Everolimus, lanreotide, octreotide and sunitinib for treating advanced neuroendocrine tumours

Cancer

Endocrine and metabolic

2 January 2024

Published on 04 Jan 2022
Last Updated on 02 Jan 2024

Everolimus, lanreotide, octreotide and sunitinib for treating advanced neuroendocrine tumours Guidance is outdated and has been withdrawn on 2 Jan 2024.

The Plain English Summary (PES) has been updated on 2 Jan 2024.

Everolimus, lanreotide, octreotide and sunitinb for treating advanced neuroendocrine tumours (Withdrawn 2 Jan 2024) [PDF, 189 KB]

PES Treatments for advanced neuroendocrine tumours (Updated 2 Jan 2024) [PDF, 159 KB]